NFKB1 and non-Hodgkin lymphoma: NFκB pathway deregulation contributes to oncogenesis in B-cell malignancies and is detected in both aggressive (diffuse large B-cell lymphoma [DLBCL]) and indolent (chronic lymphocytic leukemia/small lymphocytic lymphoma [CLL]) non-Hodgkin lymphoma (NHL) subtypes [12, 13].